Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate: Comparative Study With Filgotinib and Tocilizumab Examined by Clinical Index as Well as Musculoskeletal Ultrasound Assessment

NCT05090410 is registered in ClinicalTrials.gov with Atsushi Kawakami as lead sponsor.

NCT NCT05090410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05090410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate: Comparative Study With Filgotinib and Tocilizumab Examined by Clinical Index as Well as Musculoskeletal Ultrasound Assessment
Lead sponsor
Atsushi Kawakami
Phase
Phase 3
Overall status
Unknown status
Start date
March 3, 2021
Completion date
December 31, 2023
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biomarker, il-6 inhibitor, jak inhibitor, musculoskeletal ultrasound, rheumatoid arthritis